InterMune Announces Progress on Pirfenidone in IPF
* Initiating planned roll-over study for CAPACITY patients in Q3
* Patient retention and conduct of Phase 3 CAPACITY program remain excellent to date
* Abstract of Shionogi Phase 3 pirfenidone study now available on ATS website
BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with id…
Continue
Posted on April 22nd, 2008 at 5:32pm —
No Comments (Add)
Comment Wall
You need to be a member of nodrama to add comments!
Join this network
No comments yet!